QPS Announces New Translational Medicine Department

NEWARK, Del.--(Business Wire)--
Dr. LingSing K. Chen has been chosen to head the new Translational
Medicine department at QPS, a leading provider of research services
for the pharmaceutical industry.

"In its Critical Path Initiative, the FDA identified -- correctly,
we believe -- the need for this country to make significant
improvements to the process under which new drugs are developed," said
Dr. Ben Chien, QPS president and CEO. "By adding a department of
Translational Medicine, we hope to play an integral role in the
process of moving research discoveries from the laboratory into
clinical practice more rapidly."

Translational medicine is a relatively recent scientific
discipline that refers to the "translation" of basic research into
real therapies for patients. Since the emphasis is on a seamless
linkage between the laboratory and the patient, the practice is often
referred to as "bench to bedside" research.

"The remarkable growth in our biomarkers business areas led us to
consider this path," Dr. Chien said. "QPS considers the creation of a
Translational Medicine department pivotal to providing new
technologies to support preclinical and clinical drug development
worldwide." Chien noted that many QPS clients have already formed
Translational Medicine units to facilitate the interaction between
basic research and clinical medicine, particularly in clinical trials.

Chien said QPS would combine two existing groups, Immunobiomarker
and Molecular Biology, to form the new department. Dr. LingSing K.
Chen, former executive director of the Molecular Biology group, will
head QPS' new Translational Medicine department.

"Dr. Chen is a founding member of our Molecular Biology group and
has established very diverse capabilities within a short period of
time," Dr. Chien said. "She is a determined leader with a great deal
of entrepreneurial spirit and I have every reason to believe in the
success of our new venture."

Prior to joining QPS, Dr. Chen held executive positions at Wyeth
Pharmaceuticals and as a senior advisor to the Industrial Technology
Research Institute (ITRI) in Taiwan. Dr. Chen received her MA and PhD
in molecular biology from Princeton University and her BS in biology
from National Taiwan University.

QPS
Dr. Ben Chien, 302-369-5601

Copyright Business Wire 2008